We first showed that topical application of HCRG21 exhibits therapeutic effects on ACD and psoriasis by inhibiting inflammatory immune responses and relieving clinical manifestations via TRPV1-associated suppression of cytokine gene expression. Here, TRPV1 is linked to granular corneal dystrophy type II.